Abstracts Archive - Page 1348 of 2425 - ACR Meeting Abstracts

Abstract Number: 2137 • 2017 ACR/ARHP Annual Meeting
Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients
Vladislav Tsaltskan¹, Annette Aldous², Sam Serafi¹, Heidi Sami¹, Gulnara Mamyrova¹, Frederick W Miller³, Sam Simmens², Rodolfo Curiel¹, Olcay Y. Jones⁴ and Lisa G Rider³, ¹Department of Rheumatology, George Washington University, Washington, DC, ²Department of Epidemiology and Biostatistics, George Washington University Milken Institute School of Public Health, Washington, DC, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are rare, autoimmune chronic muscle diseases of childhood with significant potential long-term morbidity. In this study we investigate associations…
Abstract Number: 2138 • 2017 ACR/ARHP Annual Meeting
Predictive Factors for Achievement of Sustained Remission with Polymyositis/Dermatomyositis: A Retrospective Single Center Cohort Study in Japan
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Polymyositis (PM), dermatomyositis (DM), and clinically amyopathic DM (CADM) are systemic inflammatory diseases that affect skeletal muscle, skin, and other organs, such as lungs,…
Abstract Number: 2139 • 2017 ACR/ARHP Annual Meeting
Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: PM and DM are inflammatory myopathies, sometimes complicated by interstitial lung disease (ILD), myocarditis, arthritis, and malignancies. The intensity of immunosuppressive therapies depends on…
Abstract Number: 2140 • 2017 ACR/ARHP Annual Meeting
Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry
Lisa G Rider¹, Payam Noroozi Farhadi¹, Nastaran Bayat¹, Jesse Wilkerson², Abdullah Faiq¹, John McGrath², Hermine I. Brunner³, Bob Goldberg⁴ and Frederick W Miller¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Social and Scientific Systems, Inc., Durham, NC, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴The Myositis Association, Alexandria, VA
Background/Purpose: Myositis is a rare systemic autoimmune disease with suspected environmental and genetic risk factors, but little is known about specific infections and medications that…
Abstract Number: 2141 • 2017 ACR/ARHP Annual Meeting
Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage
Hans Prakash¹, Diego Song¹, Daniel Lichy¹, Pranay Rao², Mina Jain³, Joseph Shrader³, Frederick W Miller⁴, Adam Schiffenbauer⁵, Alexander Gorbach¹ and Lisa G Rider⁵, ¹National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, ²National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, bethesda, MD, ³Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD, ⁴Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁵Environmental Autoimmunity Grp, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: To assess microvascular structure and function in patients with adult dermatomyositis (DM) and juvenile dermatomyositis (JDM), we have designed and built a mobile, high-resolution…
Abstract Number: 2142 • 2017 ACR/ARHP Annual Meeting
Autoantibodies Recognizing Cytosolic 5’-Nucleotidase 1A Are Associated with More Severe Disease in Patients with Juvenile Myositis
Richard Yeker¹, Iago Pinal-Fernandez², Takayuki Kishi³, Ira N. Targoff⁴, Frederick W Miller³, Lisa G Rider³ and Andrew Mammen⁵, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD
Background/Purpose: Autoantibodies recognizing cytosolic 5’-nucleotidase 1A (NT5C1A) are present in the sera of adults with myositis and other autoimmune diseases. They are especially prevalent in…
Abstract Number: 2143 • 2017 ACR/ARHP Annual Meeting
Circulating Endothelial Cells and Endothelial Activation Markers As Disease Activity Measures in Idiopathic Inflammatory Myopathies
Takayuki Kishi¹, Jonathan Chipman¹, Maryalice Stetler-Stevenson², Khanh Nghiem³, Melvina Evereklian¹, Margaret E. Rick³, Frederick W Miller¹ and Lisa G Rider¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, ³Coagulation Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases with chronic muscle inflammation and microvasculopathy of muscle and skin capillaries. Circulating endothelial cells (CECs),…
Abstract Number: 2144 • 2017 ACR/ARHP Annual Meeting
Multiple Serum Cytokine and Chemokine Profiling to Identify Combinational Biomarkers Toward Patients of Polymyositis/Dermatomyositis Complicated with Rapidly Progressive Interstitial Lung Disease
Toshimasa Shimizu¹, Tomohiro Koga^1,2, Yoshiro Horai³, Keita Fujikawa⁴, Yushiro Endo¹, Sousuke Tsuji¹, Ayuko Takatani¹, Masataka Umeda¹, Shoichi Fukui¹, Remi Sumiyoshi¹, Ayako Nishino¹, Shinya Kawashiri¹, Naoki Iwamoto¹, Takashi Igawa¹, Kunihiro Ichinose¹, Mami Tamai¹, Noriho Sakamoto⁵, Hideki Nakamura¹, Tomoki Origuchi⁶, Hiroshi Mukae⁵, Masataka Kuwana⁷ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ³Department of Rheumatology, National Hospital Nagasaki Medical Center, Nagasaki, Japan, ⁴Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan, ⁵Department of RespiratoryMedicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁷Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Polymyositis (PM)/dermatomyositis (DM) is a chronic inflammatory disorders involved in skeletal muscles. Interstitial lung disease (ILD) complicated with PM/DM patients is often developed as…
Abstract Number: 2145 • 2017 ACR/ARHP Annual Meeting
Anti-CXCR3 Antibody Suppresses Inflammation in C Protein-Induced Myositis Model
Ji Yong Choi¹, Joo Youn Lee², Ji Soo Park³, Sehui Shon³, Kathleen Phillips⁴, Eun Young Lee¹, Eun Bong Lee¹ and Yeong Wook Song^3,5, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ²Department of Molecular medicine and biopharmaceutical science, Seoul National University, seoul, Korea, Republic of (South), ³Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South), ⁴Pfizer Inc. Cambridge, MA. USA, Cambridge, MA, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: CXCR3 is a chemokine receptor that plays an important role in T cell chemotaxis in human autoimmune diseases. CXCR3, which is activated by ligand…
Abstract Number: 2146 • 2017 ACR/ARHP Annual Meeting
CD4+CXCR4+t Cells in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease
Kaiwen Wang¹, Jangfeng Zhao¹, Zhiwei Chen¹, Ting Li¹, Xiaoming Tan², Yu Zheng², Liyang Gu¹, Li Guo¹, Fangfang Sun¹, Haiting Wang¹, Jiajie Li¹, Xiaodong Wang¹, Gabriela Riemekasten³ and Shuang Ye⁴, ¹Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Department of Pulmonology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³University Hospital Schleswig-Holstein, Campus Lübeck, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, ⁴Department of Rheumatology, Renji Hospital South Campus, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: The clinical and mechanistic relevance of peripheral CD4+CXCR4+ T cells in idiopathic inflammatory myopathy (IIM)-associated interstitial lung disease (IIM-ILD) is not known. Methods: Patients…
Abstract Number: 2147 • 2017 ACR/ARHP Annual Meeting
Dysphagia in Inflammatory Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing
Alba Azola¹, Tae Chung², Rachel Mulheren², Genevieve Mckeon², Lisa Christopher-Stine³ and Jeffrey Palmer², ¹Physical Medicine and Rehabilitation, Johns Hopkins University, Lutherville, MD, ²Johns Hopkins University, Baltimore, MD, ³Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The prevalence of dysphagia in patients with inflammatory myopathies has been reported to be as high as 60% (1). Aspiration pneumonia is one of…
Abstract Number: 2148 • 2017 ACR/ARHP Annual Meeting
Association of the Paraoxonase 1 Q192R Genetic Polymorphism with Disease Activity in Dermatomyositis
Sangmee Bae¹, Buzand Oganesian², Tyler Dowd³, Ilana Golub¹, Ani Shahbazian⁴, Jennifer Wang³, Srinivasa T. Reddy⁵ and Christina Charles-Schoeman¹, ¹University of California, Los Angeles, Los Angeles, CA, ²Medicine-Rheumatology, University of California, Los Angeles, Los ANgeles, CA, ³UCLA, Los Angeles, CA, ⁴Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Medicine-Cardiology, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Injury to the vascular endothelium is implicated in the pathogenesis of dermatomyositis (DM). Normal high density lipoprotein (HDL) protects the vascular endothelium from damage…
Abstract Number: 2149 • 2017 ACR/ARHP Annual Meeting
Statin Use in a Longitudinal Cohort of Patients with Idiopathic Inflammatory Myopathies
Sangmee Bae¹, Ilana Golub¹, Buzand Oganesian² and Christina Charles-Schoeman¹, ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los angeles, CA
Background/Purpose: Patients(pts) with idiopathic inflammatory myopathies (IIM) have an increased risk of cardiovascular (CV) disease. Statins reduce CV risk but have been associated with myalgias,…
Abstract Number: 2150 • 2017 ACR/ARHP Annual Meeting
Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama, Ryusuke Yoshimi, Yosuke Kunishita, Daiga Kishimoto, Yohei Kirino and Hideaki Nakajima, Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Although intensive immunosuppressive treatment are necessary for the severe cases with polymyositis (PM)/dermatomyositis (DM), the prognostic factors or disease activity indices for PM/DM have…
Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama^1,2, Ryusuke Yoshimi^1,2, Maasa Tamura^2,3, Naoki Hamada^1,2, Hideto Nagai^1,2, Naomi Tsuchida^1,4, Yosuke Kunishita^1,2, Yutaro Soejima^1,2, Daiga Kishimoto^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^1,5, Yohei Kirino^1,2, Shigeru Ohno^1,6 and Hideaki Nakajima², ¹Y-CURD Study Group, Yokohama, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Y-CURD Study Group, Yokohma, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Rheumatic Disease Center, Yokohama City University Medical Center, Yokohama, Japan, ⁶Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].